Controlling Hematopoiesis Through Sumoylation-dependent Regulation of a GATA Factor
Overview
Affiliations
GATA factors establish transcriptional networks that control fundamental developmental processes. Whereas the regulator of hematopoiesis GATA-1 is subject to multiple posttranslational modifications, how these modifications influence GATA-1 function at endogenous loci is unknown. We demonstrate that sumoylation of GATA-1 K137 promotes transcriptional activation only at target genes requiring the coregulator Friend of GATA-1 (FOG-1). A mutation of GATA-1 V205G that disrupts FOG-1 binding and K137 mutations yielded similar phenotypes, although sumoylation was FOG-1 independent, and FOG-1 binding did not require sumoylation. Both mutations dysregulated GATA-1 chromatin occupancy at select sites, FOG-1-dependent gene expression, and were rescued by tethering SUMO-1. While FOG-1- and SUMO-1-dependent genes migrated away from the nuclear periphery upon erythroid maturation, FOG-1- and SUMO-1-independent genes persisted at the periphery. These results illustrate a mechanism that controls trans-acting factor function in a locus-specific manner, and differentially regulated members of the target gene ensemble reside in distinct subnuclear compartments.
ZFP451-mediated SUMOylation of SATB2 drives embryonic stem cell differentiation.
Antonio Urrutia G, Ramachandran H, Cauchy P, Boo K, Ramamoorthy S, Boller S Genes Dev. 2021; 35(15-16):1142-1160.
PMID: 34244292 PMC: 8336893. DOI: 10.1101/gad.345843.120.
Boulanger M, Chakraborty M, Tempe D, Piechaczyk M, Bossis G Molecules. 2021; 26(4).
PMID: 33562565 PMC: 7915335. DOI: 10.3390/molecules26040828.
Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting.
Liu H, Weng W, Guo R, Zhou J, Xue J, Zhong S Cell Death Differ. 2020; 27(11):3146-3161.
PMID: 32483381 PMC: 7560653. DOI: 10.1038/s41418-020-0569-1.
Creed T, Baldeosingh R, Eberly C, Schlee C, Kim M, Cutler J Development. 2019; 147(1).
PMID: 31806659 PMC: 6983716. DOI: 10.1242/dev.177022.
Blood disease-causing and -suppressing transcriptional enhancers: general principles and mechanisms.
Bresnick E, Johnson K Blood Adv. 2019; 3(13):2045-2056.
PMID: 31289032 PMC: 6616255. DOI: 10.1182/bloodadvances.2019000378.